

Special Issue

Molecular Biomarkers and Precision Medicine for Alzheimer

Message from the Guest Editor

The diagnosis of Alzheimer's disease (AD) is particularly challenging in the prodromal stages, when neuropathological changes might be present but symptoms are still mild, and in atypical clinical presentations in which the differential diagnosis between AD and other neurodegenerative dementia could be difficult due to overlapping symptoms. It is therefore particularly important to identify potential biomarkers that can be used in the early detection of AD, i.e., before clinical signs appear, as well as to distinguish between AD and other types of dementia. In this Special Issue, the current knowledge as well as future perspectives on the role of biomarkers in screening and differential diagnosis of Alzheimer's disease will be discussed. In particular, papers investigating the role of current and future CSF and blood biomarkers, genetic factors involved in cognitive decline, and molecular imaging biomarkers are requested.

Guest Editor

Dr. Valentina Bessi

Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy

Deadline for manuscript submissions

closed (30 March 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/64766

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).